Easywell Biomedicals (ROCO:1799) Beta: 0.9975 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1799 Easywell Biomedicals Inc ROCO:1799
55 GF Score
Price NT$32.25
GF Value NT$75.37
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Easywell Biomedicals Beta?

Easywell Biomedicals ROCO:1799 -5.43% 55 Beta is 0.9975 as of Jul. 17, 2026. GuruFocus rates ROCO:1799 with a GF Score™ of 55/100 and a GF Value™ of NT$75.37 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-17), Easywell Biomedicals's Beta is 0.9975.


Easywell Biomedicals  (ROCO:1799) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Easywell Biomedicals Beta Related Terms


Easywell Biomedicals Beta Historical Data

* Premium members only.

The historical data trend for Easywell Biomedicals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Easywell Biomedicals Beta Chart

Easywell Biomedicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.13 0.68 0.38 0.88 0.00

Easywell Biomedicals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.00 0.00 0.00 0.00

ROCO:1799 vs ZTS, UTHR: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Easywell Biomedicals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Easywell Biomedicals Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Easywell Biomedicals's Beta distribution charts can be found below:

* The bar in red indicates where Easywell Biomedicals's Beta falls into.


ROCO:1799
55GF Score
Easywell Biomedicals Inc ROCO:1799
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Easywell Biomedicals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.9975 mean?
Easywell Biomedicals (ROCO:1799) has a Beta of 0.9975 as of Jul. 17, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Easywell Biomedicals and its competitors.
Is Easywell Biomedicals' Beta too high?
Easywell Biomedicals' current Beta is 0.9975. Overall, Easywell Biomedicals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' Beta compare to ZTS and UTHR?
Easywell Biomedicals' Beta of 0.9975 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Easywell Biomedicals and its competitors. Easywell Biomedicals's current Beta is 0.9975. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$75.37, compared to a current price of NT$32.25 — trading 57.2% below its estimated fair value. The current Beta is 0.9975. Easywell Biomedicals' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current Beta is 0.9975 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?

Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued. The current stock price of NT$32.25 is trading 57.2% below its estimated GF Value™ of NT$75.37. GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.

Key valuation signals for ROCO:1799:

  • Beta: 0.9975
  • GF Value™: NT$75.37 vs. price of NT$32.25 (57.2% below fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Easywell Biomedicals Business Description

Address No.10, Yanfa 2nd Road, Hsinchu Science Park, 1st floor, Hsinchu, TWN, 30076
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
55GF Score

Get the complete analysis for ROCO:1799

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.25
Price
NT$75.37
GF Value